Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials

Jihyun An, Joo Hyun Sohn

Clin Mol Hepatol. 2023;29(Suppl):S268-S275. Published online December 20, 2022

DOI: https://doi.org/10.3350/cmh.2022.0437

View: 2078 Download: 161 Citations: 6

Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis

Yi-wen Shi, Jian-Gao Fan

Clin Mol Hepatol. 2023;29(Suppl):S228-S243. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0401

View: 2171 Download: 91

Original Article

Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis

Ha Il Kim, Jihyun An, Seungbong Han, Ju Hyun Shim

Clin Mol Hepatol. 2023;29(4):1013-1028. Published online July 5, 2023

DOI: https://doi.org/10.3350/cmh.2023.0131

View: 547 Download: 58

Snapshot

HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?

Soon Kyu Lee, Jung Hyun Kwon

Clin Mol Hepatol. 2023;29(3):825-827. Published online May 31, 2023

DOI: https://doi.org/10.3350/cmh.2023.0185

View: 917 Download: 64

Original Article

Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients

Xiaoning Wu, Xiaoqian Xu, Jialing Zhou, Yameng Sun, Huiguo Ding, Wen Xie, Guofeng Chen, Anlin Ma, HongXin Piao, Bingqiong Wang, Shuyan Chen, Tongtong Meng, Xiaojuan Ou, Hwai-I Yang, Jidong Jia, Yuanyuan Kong, Hong You

Clin Mol Hepatol. 2023;29(3):747-762. Published online May 10, 2023

DOI: https://doi.org/10.3350/cmh.2023.0121

View: 1180 Download: 101

Review

Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity

Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi

Clin Mol Hepatol. 2023;29(3):593-604. Published online February 13, 2023

DOI: https://doi.org/10.3350/cmh.2022.0391

View: 2107 Download: 229 Citations: 3

Guideline

KASL clinical practice guidelines for management of autoimmune hepatitis 2022

Clin Mol Hepatol. 2023;29(3):542-592. Published online May 3, 2023

DOI: https://doi.org/10.3350/cmh.2023.0087

View: 1539 Download: 193

Editorial

The imitator of immune-tolerant chronic hepatitis B: A killer in disguise

Moon Haeng Hur, Jeong-Hoon Lee

Clin Mol Hepatol. 2023;29(2):363-366. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0079

View: 1464 Download: 63 Citation: 1

The clinical management of hepatocellular carcinoma in China: Progress and challenges

Shan Shan, Jidong Jia

Clin Mol Hepatol. 2023;29(2):339-341. Published online March 16, 2023

DOI: https://doi.org/10.3350/cmh.2023.0077

View: 1561 Download: 67

What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?

Min Kyung Park, Yoon Jun Kim

Clin Mol Hepatol. 2023;29(2):332-334. Published online March 16, 2023

DOI: https://doi.org/10.3350/cmh.2023.0080

View: 1412 Download: 31

Review

The role of different viral biomarkers on the management of chronic hepatitis B

Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Wai Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(2):263-276. Published online January 19, 2023

DOI: https://doi.org/10.3350/cmh.2022.0448

View: 2781 Download: 233 Citation: 1

Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective

Diyang Xie, Jieyi Shi, Jian Zhou, Jia Fan, Qiang Gao

Clin Mol Hepatol. 2023;29(2):206-216. Published online December 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0402

View: 3158 Download: 318 Citations: 5

Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective

Myung Ji Goh, Dong Hyun Sinn, Jong Man Kim, Min Woo Lee, Dong Ho Hyun, Jeong Il Yu, Jung Yong Hong, Moon Seok Choi

Clin Mol Hepatol. 2023;29(2):197-205. Published online January 5, 2023

DOI: https://doi.org/10.3350/cmh.2022.0404

View: 2658 Download: 195 Citations: 3

Correspondence

Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB”

Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(1):191-193. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0410

View: 1772 Download: 48

Original Article

Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B

Lung-Yi Mak, Danny Wong, Alison Kuchta, Martina Hilfiker, Aaron Hamilton, Ning Chow, XianHua Mao, Wai Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(1):146-162. Published online August 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0172

View: 3580 Download: 197 Citations: 7

Review

Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases

Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim

Clin Mol Hepatol. 2022;28(3):425-472. Published online July 1, 2022

DOI: https://doi.org/10.3350/cmh.2022.0186

View: 5423 Download: 298 Citations: 9

Guideline

KASL clinical practice guidelines for management of chronic hepatitis B

Clin Mol Hepatol. 2022;28(2):276-331. Published online April 1, 2022

DOI: https://doi.org/10.3350/cmh.2022.0084 Correction in: Clin Mol Hepatol 2022;28(4):940

View: 8438 Download: 511 Citations: 26

KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease

Seong Hee Kang, Hye Won Lee, Jeong-Ju Yoo, Yuri Cho, Seung Up Kim, Tae Hee Lee, Byoung Kuk Jang, Sang Gyune Kim, Sang Bong Ahn, Haeryoung Kim, Dae Won Jun, Joon-Il Choi, Do Seon Song, Won Kim, Soung Won Jeong, Moon Young Kim, Hong Koh, Sujin Jeong, Jin-Woo Lee, Yong Kyun Cho

Clin Mol Hepatol. 2021;27(3):363-401. Published online June 22, 2021

DOI: https://doi.org/10.3350/cmh.2021.0178

View: 14449 Download: 1,143 Citations: 117

Review

Recent updates on the management of autoimmune hepatitis

Atsumasa Komori

Clin Mol Hepatol. 2021;27(1):58-69. Published online December 10, 2020

DOI: https://doi.org/10.3350/cmh.2020.0189

View: 11674 Download: 962 Citations: 38

Original Article

Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients

Jihye Kim, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik

Clin Mol Hepatol. 2020;26(4):516-528. Published online September 11, 2020

DOI: https://doi.org/10.3350/cmh.2020.0016

View: 5184 Download: 191 Citations: 32

Review

Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease

Kyung-Soo Kim, Byung-Wan Lee

Clin Mol Hepatol. 2020;26(4):430-443. Published online August 14, 2020

DOI: https://doi.org/10.3350/cmh.2020.0137

View: 8249 Download: 440 Citations: 32

Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy

Chung-Feng Huang, Ming-Lung Yu

Clin Mol Hepatol. 2020;26(3):251-260. Published online March 19, 2020

DOI: https://doi.org/10.3350/cmh.2020.0018

View: 13723 Download: 379 Citations: 37

Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure

Tommaso Lorenzo Parigi, Maria Corina Plaz Torres, Alessio Aghemo

Clin Mol Hepatol. 2019;25(4):360-365. Published online May 2, 2019

DOI: https://doi.org/10.3350/cmh.2019.0022

View: 4924 Download: 242 Citations: 10

KASL clinical practice guidelines for management of chronic hepatitis B

Clin Mol Hepatol. 2019;25(2):93-159. Published online June 12, 2019

DOI: https://doi.org/10.3350/cmh.2019.1002

View: 22616 Download: 623 Citations: 134

2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C

Clin Mol Hepatol. 2018;24(3):169-229. Published online August 10, 2018

DOI: https://doi.org/10.3350/cmh.2018.1004

View: 13507 Download: 216 Citations: 24

Original Article

Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion

Jihyun An, Kwang Sun Lee, Kang Mo Kim, Do Hyun Park, Sang Soo Lee, Danbi Lee, Ju Hyun Shim, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee

Clin Mol Hepatol. 2017;23(2):160-169. Published online May 16, 2017

DOI: https://doi.org/10.3350/cmh.2016.0088

View: 7974 Download: 231 Citations: 24

Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization

Sun Hong Yoo, Jeong Won Jang, Jung Hyun Kwon, Seung Min Jung, Bohyun Jang, Jong Young Choi

Clin Mol Hepatol. 2016;22(4):458-465. Published online December 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0054

View: 8240 Download: 129 Citations: 7

Review

Acute kidney injury in liver cirrhosis: new definition and application

Florence Wong

Clin Mol Hepatol. 2016;22(4):415-422. Published online December 14, 2016

DOI: https://doi.org/10.3350/cmh.2016.0056

View: 13290 Download: 754 Citations: 51

Case Report

A Korean patient with Guillain-Barré syndrome following acute hepatitis E whose cholestasis resolved with steroid therapy

Sung Bok Ji, Sang Soo Lee, Hee cheul Jung, Hong Jun Kim, Hyun Jin Kim, Tae Hyo Kim, Woon Tae Jung, Ok Jae Lee, Dae Hyun Song

Clin Mol Hepatol. 2016;22(3):396-399. Published online August 30, 2016

DOI: https://doi.org/10.3350/cmh.2015.0039

View: 16344 Download: 112 Citations: 8

Original Article

Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B

Han Ah Lee, Yeon Seok Seo, Seung Woon Park, Sang Jung Park, Tae Hyung Kim, Sang Jun Suh, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun, Soon Ho Um

Clin Mol Hepatol. 2016;22(3):382-389. Published online September 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0047

View: 11446 Download: 195 Citations: 19

1 | 2 | 3 |

Viewed By 7246	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 6236	A decade of liver organoids: Advances in disease modeling
Viewed By 4058	Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy
Viewed By 3461	MAFLD: How is it different from NAFLD?
Viewed By 3078	Hepatorenal syndrome: Current concepts and future perspectives

Cited By 117	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Cited By 54	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 52	From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Cited By 46	Obesity and the risk of primary liver cancer: A systematic review and meta-analysis
Cited By 46	Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis

Search